The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESH MM 2018 | Double-blind trial of denosumab vs. zoledronic acid for bone disease in NDMM
Evangelos Terpos, MD, PhD, of the University of Athens, Athens, Greece, discusses the Phase II study of denosumab vs. zoledronic acid for the treatment of bone disease in newly diagnosed multiple myeloma (MM; NCT01345019). Dr Terpos expresses his excitement about the findings, particularly due to their double-blinded nature. This interview took place at the European School of Haematology (ESH) International Conference on MM 2018, held in Mandelieu, France.
